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ABSTRACT
KULLY LYNN WOODRUFF: Optiinization Studies of the Important Drug Lead
Kahalalide F which Acts on a Novel Cancer Target RPS25
(Under the direction of Dr. Mark T. Hamann)
Kahalalide F (KF, 1) is the largest and most biologically active cyclic peptide of the
naturally occurring kahalalide family of depsipeptides. Previous evaluations of the
compound have shown significant in vitro and in vivo activity against various forms of
cancer. KF has been investigated in phase I clinical trials and is being evaluated in phase
II clinical studies. The objective of this experiment was to prepare analogues of KF
through semisynthetic modification of the parent compound to optimize activity against a
slate of pathogens, as well as cancerous cells. Data revealed that KF and analogues were
not active against malaria, leishmania, or bacteria. However, the series was active
against various strains of fungi, including Fusarium, a genus known for causing
opportunistic infections in plants, as well as humans. KF and analogues were also
evaluated for in vitro activity against 60 human cancer cell lines. Analogue 5 exhibited
greater activity than 1 against several cell lines, including leukemia, colon, ovarian, renal,
and prostate cell lines. Through the evaluations of antiprotozoal, antibacterial, and
antifungal activity, as well as the activity against a slate of human cancer cell lines, it was
revealed that semisynthetic modification of the parent compound has an affect on
activity. Further studies involving semisynthetic modification of KF could lead to vast
improvements in current drug therapies.
VI
PREFACE
The research reported in this manuscript has been incorporated into the larger work
“Lysosome and HER3 (ErbB3) Selective Anticancer Agent Kahalalide F: Semisynthetic
Modifications and Antifungal Lead-Exploration Studies” by Abbas Glolipour Shilabin,
Noer Kasanah, David E. Wedge, and Mark T. Hamann, which was published in the
Journal of Medicinal Chemistry*
* Shilabin, A. G..; Kasanah, K..; Wedge, D. E.; Hamann, M. T. Lysosome and HER3 (ErbB3) selective
anticancer agent kahalalide F: semis)mthetic modifications and antifimgal lead-exploration studies. J. Med.
Chem. 2007, 50, 4340-4350.
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There is no question that natural products are a source of promise in the areas of
drug discovery and development. According to the Natural Products Branch (NPB) of
the National Cancer Institute (NCI), “There are good precedents for looking to nature for
The NCI states that approximately twenty-five percent of modem
medicines come fi-om plants that were used previously in a more traditional form. Dmgs,
including aspirin, morphine and many antibiotics, were originally derived fi-om natural
products, including plants, bacteria, fiingi and marine invertebrates. Many of the current
chemotherapy dmgs were also derived fi-om natural products. For instance, Taxol, a
common dmg used today in the treatment of breast and ovarian cancer, was derived from
the bark of the Pacific yew, a tree native to the Pacific Northwest,
of the NPB, said, “Nature produces these molecules for a reason.” The compounds that
have proven useful medicinally often play a critical role in the life of the orgamsm from
which they come. The NCI cites examples such as bacteria that produce antibiotics to






The National Center for Natural Products Research (NCNPR) at the University of
Mississippi is also participating in the area of dmg discovery and development.^ The
research reported in this manuscript was completed under Dr. Mark T. Hamaim, research
professor with NCNPR. Much of Hamann’s research focuses on the development of
1
marine natural product drug leads via marine derived secondary metabolites. Reported
research focuses on the kahalalides.
B. KAHALALIDEF
The kahalalide family consists of a series of natural depsipeptides. They were
first isolated from the Hawaiian herbivorous marine sacoglossan mollusk Elysia
rufescens (Plakobranchidea). E. rufescens is a small, soft-bodied sacoglossan (Figure 1).
Later isolation was achieved from Bryopsis pennata (Bryopsidaceae), the green algal diet
of E. rufescens. The kahalalides range in size and composition from a C31 tripeptide
to a CIS tridecapeptide. The largest and most biologically active cyclic peptide of the
kahalalide family is the tridecapeptide kahalalide F (KF, 1). KF has molecular formula
C75H124N14O16 and mass 1477.9408 [M + Previous evaluations of the parent
compound KF have shown significant in vitro and in vivo activity against various forms
of cancer, including colon, breast, non-small-cell lung, and prostate. KF has been
investigated in phase I clinical trials for androgen-refractory prostate
phase II clinical trials for liver cancer, non-small-cell lung cancer (NSCLC), and
melanoma. A number of patients with advanced NSCLC, hepatocarcinoma (HC), and
advanced malignant melanoma (AMM) have responded positively to treatment with
KF.*^ However, structure-activity relationship (SAR) studies involving KF have not been
reported due to its limited availability as a natural product.
The significant activity of KF against serious forms of cancer has prompted





acts on cell hsosomes. causing targeted cells to swell, leading to oncosis, or cellular
death b\- s\^■elling.
kinase ErhB3 (HER3) has an affect on tlie mechanism of action."’ .A recent smdy by
V
Piggott and Karuso emplo\ed chemical proteomics vvith tlie goal of isolating and
l.'.iC'
Studies ha^'e also shown that inhibition of the receptor nnosine
identify ing the actual cellular receptor of KF. The study cited human ribosomal protein
S25 (RPS25) as a binding paitner for tlie compound. RPS25 is located at tlie surface of
the 40S ribosomal subunit in eukan'otic cells and may aid in stability of the complex. It
is likeh' that RPS25 is only one step in the series of events that evenmalh' leads to
16
disruption of lysosomes and cell death by oncosis.
KF is covered b> LkS. patent number 6,274.551 and has been assigned to the
phamiaceutical compan}' PharmaMar S.A. in Madrid. Spain for further development.
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Figure 2. Kahalalide F and key functional groups
C. TARGETS
1. microorganisms
The Department of Health and Human Services Centers of Disease Control and
Prevention (CDC) cites the development of dmg resistance by microorganisms as a
pressing public health concern. As these organisms develop resistance to current
therapies, research devoted to the discovery of new treatment methods is critical.^^ For
this reason, the activity of KF and its derivatives were evaluated for activity against
several key orgamsms, including the fungi Fusarium spp., Candida albicans.
Cryptococcus neoformans, and Aspergillus fumigatus; the bacteria Escherichia coli.
Pseudomonas aeruginosa, Methicillin resistant Staphylococcus aureus, Mycobacterium
tuberculosis, and Mycobacterium intracellulare; and the protozoa Plasmodium
falciparum and Leishmania donovani.
4
Fusahum, a large genus of the Phylum Ascomycota, is a filamentous fimgus
common to tropical and subtropical areas. The genus Fusarium contains over twenty
species of fungi, including Fusarium solani and Fusarium oxysporum. It is commonly
found associated with such commodities as rice and soybeans.*^ Along with being a well
known plant pathogen, Fusarium spp. can also cause various infections in humans,
Fusariosis is commonly found in
immunocompromised patients who have undergone transplants or chemotherapy
treatment. It is also developing as an opportunistic infection in AIDS patients. The
treatment options for patients infected with Fusarium spp. are limited due to its intense
drug resistance. Because of the difficulty in treating the disease, fiisariosis is often fatal
in its more invasive form.^^ The activity of KF and its derivatives was also evaluated for
activity against the fimgi Candida albicans. Cryptococcus neoformans, and Aspergillus
fumigatus. Like Fusarium spp., these microorganisms cause opportunistic infections in
immunocompromised patients.
Activity of KF and analogues was also tested against the parasites Plasmodium
falciparum and Leishmania donovani. Plasmodium falciparum is the cause of the most
severe form of malaria. The CDC reports that 350-500 million cases of malaria occur
worldwide each year. Over one million cases are fatal, with P. falciparum being the most
deadly. The parasite is spread by certain infected mosquitoes of the genus Anopheles.
The parasite Leishmania donovani causes visceral leishmaniasis. Visceral leishmaniasis
affects internal organs, including the spleen, liver, and bone marrow. The CDC reports
that over 500,000 new cases of visceral leishmaniasis are diagnosed each year. Major
collectively referred to as fusariosis.
20
5
countries affected include India, Sudan, and Brazil. The parasite is spread by infected
17
sand flies.
The activity of KF and its derivatives was also evaluated against the bacteria
Mycobacterium tuberculosis, Escherichia coli. Pseudomonas aeruginosa, Methicillin
resistant Staphylococcus aureus, and Mycobacterium intracellulare. Mycobacterium
tuberculosis is the bacterium that causes tuberculosis (TB). M tuberculosis usually
attacks the lungs, but can also affect the spine, kidney, and brain. The bacteria spread
through the air, making the disease extremely contagious. Many cases of TB develop in
patients with compromised immune systems, such as those with AIDS and HTV. TB is a
leading cause of death worldwide, surpassing malaria and AIDS.^^ In many countries the
Bacillus Calmette-Guerin (BCG) vaccine is administered. However, many clinical trials
have placed little value on the vaccine. Often a cocktail of drugs is used in treatment.
Developing drug resistance is a critical concern with TB, because of the current
widespread nature of the disease. The bacteria Escherichia coli. Pseudomonas
aeruginosa, Methicillin resistant Staphylococcus aureus, and Mycobacterium
intracellulare, which cause opportunistic infections in immunocompromised patients,




As previously stated, evaluations of KF have shown significant activity against
various forms of cancer, including colon, breast, non-small-cell  lung, and prostate. KF
has been investigated in phase I and phase II clinical trials for androgen-refractory
6
prostate cancer^ ̂ and for liver cancer, NSCLC, and melanoma, respectively,
with advanced NSCLC, HC, and AMM have also responded positively to treatment with
Patients
12
Because KF has already shown activity against several serious forms of cancer, theKF.
activity of the parent compound and analogues was evaluated against a slate of 60 human
cancer cell lines. The cell lines tested included lung, leukemia, colon, central nervous
system (CNS), melanoma, ovarian, renal, prostate, and breast. The activity of KF against
each of these cell lines was compared with the activity of the current chemotherapy drug
Paclitaxel against the slate of cells. Paclitaxel is marketed under the U.S. brand name
Taxol. As previously discussed, the compound was derived from the bark of the Pacific
yew, a tree native to the Pacific Northwest. It is commonly used today in the treatment of
Many other chemotherapy drugs were also derived from
natural products. For instance, vincristine is an alkaloid isolated from the Madagascar
21
breast and ovarian cancer.
periwinkle (Vinca rosea). It is marketed in the U.S. under the name Oncovin and is
commonly used in the treatment of non-Hodgkin’s lymphoma.^* The drugs derived from
each of these natural products are currently being used in chemotherapy treatments. This
precedent provides promise for the continued potential of KF.
Because of the sigmficant activity of BCF against various forms of cancer,
unlocking the mechanism of action of the compound has become a critical area of study.
As previously discussed, studies have shown that inhibition of the receptor tyrosine
kinase ErbB3 (HER3) has an affect on the mechanism of action of the compound. The
activity of KF against several cell types has been linked with protein expression levels of
ErbB3, which suggests that ErbB3 could play a role in determining the effectiveness of
KF in the treatment of individual patients.
11,23
Like HER3, HERl and HER2 are
7
members of the human epidermal growth factor receptor family of receptor tyrosine
kinases. There are currently drugs on the market that act on HERl and HER2 receptors.
For example, Herceptin (trastuzumab), a monoclonal antibody, acts by inducing
cytotoxicity against cells overexpressing HER2. Herceptin has been used in the
treatment of breast cancer caused by this overexpression. HERl inhibiting drugs are also
available. Examples include Erbitux (cetuximab), Iressa (gefitinib), and Tarceva
(erlotinib hydrocloride).^' Unlike available drugs for HERl and HER2 related cancers,
there are currently no HER3 inhibiting dmgs. Therefore, KF and analogues serve as
promising candidates for inhibition of HER3 receptors in tumor cells.
8
n. METHODS
General Experimental Procedures. The and NMR spectra were recorded in
Bruker DRX NRM spectrometer operating at 400 MHz for
and 100 mHz for NMR. Chemical shift (5) values are expressed in parts per million
(ppm) and are referenced to the residual solvent signals of DMSO-^/e and MeOD at 5h/ 5c
2.50/39.5 and 3.31,4.78/49.1, respectively. UV and IR spectra were respectively
obtained using a Perkin-Elmer Lambda 3B UV/Vis spectrophotometer  and an AATI
Mattson Genesis series FTIR. Optical rotations where measured with a JASCO DIP-310
digital polarimeter. The High Resolution ESI-MS spectra were measured using a Bruker
Daltonic (GmbH, Germany) microTOF series with electrospray ionization. TLC analysis
was carried out on precoated silica gel G254 aluminum plates.
^MSO-de and MeOD on a
CHEMICALS. Kahalalide F was prepared according to the previously reported methods
with some modifications."* The animals (Elysia rufescens) were collected by snorkeling
at low tide near Black Point, Oahu in Hawaii. The ethanolic extraction of freeze-dried
animals was subjected to flash chromatography on silica gel (EtOAc/MeOH).
Preparative HPLC using Phenomenex 100 mm RP C8 column (250 mm x 100 mm) and a
gradient MeCN (0.05% TFA)/H20, followed by further HPLC purification on amino
column (250 mm x 22 mm) using gradient EtOAc/MeOH afforded KF (1) as a white
amorphous powder. All reagents and solvents were obtained from commercial vendors
and were utilized without further purification.
9
Kahalalide G (2). A solution of kahalalide F free base (30 mg, 20 /miol) and potassium
carbonate (0.2 g) in H20/Me0H (1:2) (10 mL) was stirred at room temperature for 8 h.
The mixture was portioned between CHCI3/IPA (2:1) and water. The organic layer was
dried over Na2S04, and the solvent was evaporated under reduced pressure. Reversed-
phase HPLC using gradient MeCN (0.05% TFA)/water afforded 28.4 mg (95%) of KG
(2) as a white powder.^ Yield 95.0%; [af - 12.3‘ (c = 0.20, MeOH); UV X,„ax (MeOH)
195 nm; IR neat (NaCl) 3281 (s, hr), 2966 (s), 2937 (s), 1732 (s), 1636 (s), 1541 (s), 1456
(s), 1204 (s), 1139 (s) cm"'; HRESIMS m/z calcd for C75H127N14O17 [M + H]^ 1519.9498,
found 1519.9466.
1 2
Figure 3. Conversion of kahalalide F (1) to kahalalide G (2)
Monoacetylated>KF (3). To a suspension of kahalalide F free base (30 mg, 20 in
anhydrous dichloromethane (5 mL) were added acetic anhydride (0.4 mL) and boron
trifluoride-diethyl etherate (0.2 mL) at room temperature under a nitrogen atmosphere.
The mixture was stirred for 5 min, poured into a cool saturated NaHCOs solution (20
L), and extracted with CHCI3APA (2:1)(2 x 10 mL). The combined organic layers
were dried over Na2S04, and the solvent was evaporated under reduced pressure. The
purification was carried out with HPLC using a Phenomenex Luna RP C8 column (250
mm X 22 mm) eluted with a gradient water/MeCN (0.05% TFA) to give 20.7 mg (68%)
m
10
of monoacetyl KF (3). Yield 68.0%; [o]“d - 10.5' (c = 0.25, MeOH); UV (MeOH)
194, 222 nm; IR neat (NaCl) 3283 (s, br), 2967 (s), 2936 (s), 1735 (s), 1654 (s), 1458 (s),
1389 (s), 1140 (s) cm"'; HRESIMS mlz calcd for C75H127N14O17 [M + H]'^ 1519.9498,
found 1519.9478.
1
Figure 4. Conversion of 1 to monoacetylated-KF (3)
Ox0“KF (4). To a solution of Dess-Martin periodinane (22 mg, 48 //mol) in anhydrous
acetonitrile (10 mL) was added kahalalide F (60 mg, 40 //mol) in one portion and stirred
at room temperature for 1 h under nitrogen atmosphere. The reaction mixture was
quenched with 10% Na2S203/saturated aqueous NaHCOs (v/v 1:1, 20 mL) and extracted
with CHCI3/IPA (2:1) (2 x 20 mL). The combined organic layers were dried over
Na2S04, and the solvents were evaporated under reduced pressure. The residue was
subjected to preparative HPLC using a Phenomenex Luna RP C8 column (250 mm x 22
mm) eluted with gradient water/MeCN (0.05% TFA) to afford 44.2 mg (75%) of pure
- 5.4” (c 0.10, MeOH);
UV (MeOH) 195 nm; IR neat (NaCl) 3319 (s, br), 2961 (s), 2925 (s), 1731 (s), 1645
(s), 1531 (s), 1455 (s), 1392 (s) cm"'; HRESIMS mk calcd for C75H123N14O16 [M + Hf
1475.9236, found 1475.9237.




Figure 5. Conversion of 1 to Oxo-KF (4)
General Preparation of Compounds 5-11. To a solution of kahalalide F (29.5 mg, 20
jimol) and aldehyde in anhydrous methanol (5 mL) was added via 3 A molecular sieve (2
g) and stirred for 30 min at room temperature under argon followed by portionwdse
addition of sodium triacetoxyborohydride (8.5 mg, 40 pmol) over a 20 min period. The
reaction mixture was stirred for the above mentioned time at the same condition.
quenched with water (20 mL) and extracted with IPA/CHCI3 (1:2) (2 x 10 mL). The
combined organic layers were dried over anhydrous Na2S04 and the solvent was removed
The resulting residue was purified with preparative HPLC usingunder vacuum.
Phenomenex RP C8 column (250 mm x 22 mm) and eluted with gradient CH3CN (0.05
TFA)/water to yield corresponding monoalkyl-KF (major) and dialkyl-KF (minor)
products as colorless powders.
4-Fluorobenzylamino-KF (5). Starting material 4-fluorobenzaldehyde (10.6 /^L, 100
/^mol) was used and the reaction mixture was stirred for 18 h. Yield 64.5%; [a]
11.9° (c 0.25, MeOH); UV X^ax (MeOH) 196 nm; IR neat (NaCl) 3281 (s, br), 2966 (s),
2935 (s), 1774 (s), 1655 (s), 1583 (s), 1450 (s), 1204 (s) cm'*; HRESIMS m/z calcd for




Yield 3.1%; HRESMS m/z calcd forBis(4-fluorbenzyl)ainino-KF (6).
C89Hi34F2Ni40,6 [M + H]^ 194.0148, found 1694.0141.
4-pyridinylmethylamino-KF (7). Starting material 4-pyridinecarboxaldehyde (9.5 fih,
100 fimol) was used and the reaction mixture was stirred for 2 d. The preliminary stirring
-9.r(c0.19,
MeOH); UV (MeOH) 193 nm; IR neat (NaCl) 3281 (s, hr), 2965 (s), 2923 (s), 1741
(s), 1647 (s), 1541 (s), 1523 (s), 1457 (s), 1203 (s), 1139 (s) cm'^; HRESIMS m/z calcd
for C8iH,3oNi50,6 [M + Hf 1568.9815, found 1568.9814.
25
of the reaction mixture for 30 min was not completed. Yield 53.1%; [a]
2-Thienylmethylamino-KF (8). Starting material 2-thiophenecarboxaldehyde (9.2 piL,
25
100 ̂ mol) was used, and the reaction mixture was stirred for 3 d. Yield 52.3%; [a] D-
8.0“ (c 0.25, MeOH); UV (MeOH) 193 nm; IR neat (NaCl) 3283 (s, br), 2966 (s),
2936 (s), 1734 (s), 1648 (s), 1541 (s), 1524 (s), 1458 (s), 1203 (s) cm'‘; HRESIMS m/z
calcd for C8oH,29Ni40i6S [M + H]^ 1585.9768, found 1585.9769.
Bis(2-thienylmethyl)amino-KF (9).
C85H133N14O16S2 [M + H]^ 1669.9465, found 1669.9461.
Yield 12.6%; HRESIMS m/z calcd for
w-Hexylamino-KF (10). Starting material /i-hexanal (12.3 fiL, 100 //mol) was used and
the reaction mixture was stirred for 1 h. Yield 45.1%; [a]^^o - 7.2“ (c = 0.10, MeOH);
UV (MeOH) 195 nm; IR neat (NaCl) 3280 (s, br), 2964 (s), 2934 (s), 1732 (s), 1651
13
(s), 1539 (s). 1456 (s), 1203 (s) cm'‘; HRESMS m/z calcd for CgiHisrNwOie [M +
1562.0331, found 1562.0334.
Di-«-hexylamino-KF (11). Yield 25.3%; [a]“o - 18.2' (c = 0.25, MeOH); UV
(MeOH) 195 nm; IR neat (NaCl) 3282 (s, br), 2964 (s), 2935 (s), 1732 (s), 1646 (s), 1540
















Figure 6. Conversion of 1 to analogous 5-11
14
DEAC-KF-amide (16). 7-Diethylaminocoumarin-3-carboxylic acid (5.3 mg, 20.3 jimol),
HBTU [0-(benzotriazol-l-yl)-A^,A/;A^’,A^’-tetramethyl-iironium hexafluorophosphate] (9.2
mg, 24.4 jimol), and EDC [A^-ethyl-A^’-(3-dimethylaminopropyl)carbodiiinide] (4.3 pL,
24.4 jimol) were dissolved in anhydrous DMF (5 mL). A solution of kahalalide F (30.0
mg, 20.3 pmol) in anhydrous DMF (2 mL) was added portionwise over 10 min at 0 C,
followed by stirring for 1 h at room temperature. The reaction was quenched by addmg
water (10 mL) and extracted with IPA/CHCI3 (1:2) (2 x 10 mL). The combined organic
layers were dried over anhydrous Na2S04 and the solvent was evaporated under reduced
pressure. The resulting residue was purified with HPLC using an Phenomenex Luna RP
C8 column (250 mm x 22 mm) and eluted with gradient MeaCN (0.05 TFA)/water to
-9.V {c = 0.20, MeOH); UV
X^ax (MeOH) 201,422 nm; IR neat (NaCl) 3319 (s, br), 2959 (s), 2924 (s), 1731 (s), 1644
(s), 1514 (s), 1455 (s), 1233 (s), 1135 (s) cm'*; HRESIMS m/z calcd for C89H138N15O19
[M+Hf 1721.0287, found 1721.0282.
25
afford peptide 19 as white powders. Yield 84.9%; [a] D
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Figure 7. Conversion of 1 to DEAC-KF-amide (16)
15
Pathogen Production of Fusarium, F. solani (F-0007), F. oxysporium (F-OOOl), and F.
proliferatum (F0029-1) were obtained from USDA-ARS Laboratory, Natural Products
Utilization Research Unit, National Center for Natural Products Research, The University
of Mississippi. The isolates were isolated from orchid species by D. E. Wedge and
identified by Dr. W. H. Elmer, Connecticut Agricultural Experiment Station. The
cultures were stored on silica gel in the USDA-NPURU repository. The isolates were
found to be pathogenic to orchid species. Fusarium spp. Cultures were initiated on
potato dextrose agar (PDA, Difco, Detroit, Ml) from spores. Conidia were harvested
from 7 day old culture by flooding plates with 10 mL of sterile distilled water and
dislodging using an L-shape glass rod. Coni dial suspensions were filtered through sterile
Miracloth (Calbiochem-Novabiochem Corp., La Jolla, CA) to remove mycelia.
Concentration of conidia was determined photometrically at 625
curve. The concentration of conidia was 3x10^ conidia/mL. The conidia suspension
was used for one-dimensional direct bioautography and other experiments.
from a standardnm
Bioautography Assay. Each compound was dissolved in methanol at 1 mg/mL. An
amount of 100 pL of compounds was spotted on a glass thin layer chromatography plate
(TLC plate, silica gel GF, 250 pm, 10 cm x 20 cm. Uniplate, Analtech, Inc., Neward,
DE) and allowed to dry. The initial concentration of each compound tested was 100
pg/mL. After drying, the plates were sprayed with spore suspensions of Fusarium spp.
Conidial solution was prepared with potato dextrose broth 12 g/500 mL, 0.1% bacto agar,
0.1% Tween-80 and contained 3 x 10^ conidia/mL of each Fusarium spp. Plates were
placed in a moisture chamber (Pioneer Plastic, Inc., Dixon, KY) and incubated for 3 days
16
at 26 °C. After incubation, plates were removed fix)m the moisture chamber, dried at
room temperature, and exhaustively sprayed with 0.25% MTT (3-(4,5-dimethylthiazl-2-
yl)-2,5-diphenyltetrazolium bromide, Sigma) prepared in phosphate buffer. The plates
were placed back into a moisture chamber and incubated at 26 “C for 1 day and allowed
to develop. The active compounds were visualized by clear zones of fungal growth
inhibition on TLC plates with purple background. Amphotericin B, captan, benomyl, and
azoxystrobin were used as positive controls to evaluate the activity of 1 and its analogues.
Microtiter Assay. 1 and its analogues were evaluated for a dose response effect against
fungi using a 96-well microdilution broth assay (Nunc, Micro Well, Roskilde, Denmark)
at concentrations of 0.3, 3, and 30 \M against F. proliferatum, F. solani, and F.
oxysporium according to the procedure published by Wedge et al.
22
Microtiter plates
were covered with plastic lids and incubated in a growth chamber at 24 ± 1 'C and 12 h
photoperiod under 60 ± 5 pmol/m^ s'. Fungal growth was monitored photometrically by
measuring absorbance at 620 nm at 24, 48, and 72 h. Mean absorbance values and
standard error were used to evaluate fimgal growth.
Fungicidal and Fungistatic Testing. The fungicidal or fungistatic assay was conducted
to determine the action of each compound at 30 |jM. After 72 h of incubation in a
microtiter assay, 20 pL of solution of each well was cultured onto a 90 mm Petri plate
containing 10 mL of potato dextrose agar free of  1 and its analogues. The plates




observed on the subcultured plate free of compounds, and the fungistatic activity was
defined if fungal growth was observed on the subcultured plate.
Mycobacterium Tuberculosis Assay. In vitro evaluation of antimycobacterial activity
conducted with Mycobacterium tuberculosis H37Rv ATCC 27294 in BACTEC 12B
medium using mircoplate Alamar blue assay (MABA). Primary screening is evaluated at
16 pg/mL. Compounds that showed inhibition of greater than 90% are retested at a lower




III. RESULTS AND DISCUSSION
1. Semisynthesis of Kahalalide F Analogues. Methodology for the semisynthesis of
kahalalide F (KF. 1) analogues is presented in the corresponding section along with
validation of each structure. Data regarding structural validation is also presented in
Table 1.












2.74 (m) 7.19-7.28 (m, 5H,Ph) 38.7 126.8 (Ph), 128.5 (2C,Ph),
129.5 (Ph), 130.1 (Ph)
115.9 (Ph), 116.1 (Ph),
127.0 (Ph), 128.6 (2C, Ph),
129.7 (Ph), 130.3 (Ph),
132.7 (Ph), 132.8 (Ph)
124.7 (2C, Py), 126.9 (Ph),
128.7 (2C,Ph), 129.7 (Ph),
130.3 (Ph), 150.3 (2C, Py)
126.9 (Ph), 127.8 (Th),
128.6 (2C,Ph), 128.7 (Th),
129.7 (Ph), 130.2 (Ph),
130.9 mi)
14.3 (CH3),22.3(CH2),
25.8 (CHz), 26.0 (CHj),
31.1 (CHj), 126.9 (Ph),
128.6 (2C,Ph), 129.7 (Ph),
130.2 (Ph)
14.3 (CHj), 22.4 (CHz),
23.4 (CHj), 23.5 (CHj),
31.2(CH2),127.0(Ph),
128.6 (2C, Ph), 129.7 (Ph),
130.2 (Ph)
1
2.91 (m) 7.18-7.28 (m,5H, Ph),
7.49-7.52 (m, 2H, Ph),
8.77-8.80 (m, 2H, Ph)
38.5 46.65 1585.9769
2.93 (m) 7.21-7.28 (m,5H, Ph),
7.49 (m, 2H, Py), 8.66
(s, 2H,Py)
7.22-7.29 (m, 5H,Ph),
7.10 (m,Th), 7.21 (m,
Th), 7.57 (m,Th)
38.5 47.61568.9814 7.63 (m)7
2.92 (m)1573.9429 7.63 (m) 38.5 47.68
2.85 (bs) 7.21-7.27 (m, 5H, Ph),
0.61-1.55 (m,13H,
aliphatic)
1562.0334 7.59 (m) 38.510 47.6




Abbreviations: Ph = phenyl, Py = pyridine, Th = thienyl; Aliph = aliphatic
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2. Biological Evaluation of Products.
2.A. Activity in Opportunistic Infections. Kahalalide D (KD), kahalalide G (KG, 2), 1
and its analogues were evaluated in vitro for their activity against several
These microorganisms included Escherichia colU Pseudomonasmicroorganisms.
aeruginosa^ Methicillin resistant Staphylococcus aureus, Candida albicans.
Cryptococcus neoformans, Mycobacterium intracellulare and Aspergillus fumigatus, all
of which cause opportunistic infections in immunocompromised individuals. KD, 2, 1
and its analogues showed no activity against E. coli, P. aeruginosa, or Methicillin
resistant S. aureus. Only 3 and 10 showed activity against M. intracellulare. Results of
this evaluation revealed that semisynthetic modification of 1 alters antibacterial activity.
1 and its analogues also exhibited activity against C. albicans (fungus type yeast), C.
neoformans (dimorphic fungus). A. fumigatus (filamentous fungus) and Fusarium spp.
Results of this evaluation are presented in Table 2. The
concentration that yields 50% inhibition of growth (IC50), the lowest test concentration
that yields detectable growth (minimum inhibitory concentration,  MIC), and the lowest
test concentration that kills 100% of the organism (minimum fungicidal/bactericidal
concentration, MFC/MBC) were determined. Amphotericin B, a common antifungal
drug, served as a control. 1 and analogues 3, 8, and 10 exhibited activity against C
albicans, C. neoformans, and A. fumigatus. 4 and  7 were active against C. albicans and
C. neoformans. 1 was also active against A. fumigatus. 5 and 11 were active against C.
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2.B. Antiparasitic Activity. 1 and its analogues were tested against Plasmodium
falciparum, which causes one of the deadliest forms of malaria, and Leishmania
donovani. which causes visceral leishmaniasis, as previously discussed,
analogues 8 and 10 were active against L donovani. 1 and its analogues did not show
activity against P. falciparum.
17 1 and
2.C. Bioactivity against Mycobacterium tuberculosis. 1 and its analogues were tested
against Mycobacterium tuberculosis, the bacterium that causes tuberculosis.
Rifampicin, a standard drug used in the treatment of Mycobacterium infections, served as
Compounds were evaluated at 16 The minimum inhibitory
concentration (MIC), the lowest test concentration that yields detectable growth, of
compounds with greater than 90 percent inhibition at 16 /ig/mL was determined (Table
3). 3, 8, and 11 showed greater activity than 1 (67% inhibition), with inhibitions ranging
from 91-94%. These values were comparable to the standard rifampicin, which showed
inhibition of 93%. Of the three, 11 showed better potency against M tuberculosis. The
minimum inhibitory concentration of the other analogues was not determined, because as





Table 3. Minimum Inhibitor}^ Concentration (MIC) of 1 Analogues versus
Mycobacterium tuberculosis H37Rv Strains^












NT ̂ not tested. RMP rifampicin.
2.D. Bioactivity against Fusarium spp. The treatment options for patients infected
with Fusarium spp. are limited due to its intense drug resistance. For this reason, the
activity of KF and its derivatives were evaluated for antifungal activity, specifically
focusing on Fusarium spp.
Bioautography Assay. Bioautography was used to detect antifungal activity2.D.I.
against Fusarium spp. Results showed that semisynthetic modification of 1 did not have
an effect on antifungal activity. 1 and its analogues were active against F. proliferatum.
Only 4 was active against F. solani and F. oxysporium. Analogue 4, which was prepared
by oxidizing the secondary alcohol, could be a key in broadening the spectrum of activity
against Fusarium spp.
23
2.D.2. Microtiter Assay. In contrast to the bioautography assay, which revealed that 1
and its analogues were active only against F. proliferatum^ the microtiter assay revealed
that 1 and its analogues were active against F. oxysporium, F. proliferation, and F. solani
(Table 4). Activity was present at the highest concentration, 30 /zM. Table 4 shows the
percent inhibition of Fiisarium spp. after treatment with 1 and its analogues at three
different concentrations (0.3, 3.0, and 30 pM.) for 48 and 72 hours. Standards tested were
Azoxystrobin (fungicide), Captan (fungicide), and Amphotericin B (antifungal drug). At
the lowest concentration (0.3 //M), only 4 showed activity against Fusarium spp. This
activity was lost after 72 hours. Azoxystrobin showed activity against F. oxysporum and
F. solani after 48 and 72 hours of exposure. At 3.0 /^M, 7, 10, and 16 showed no activity
against Fusarium spp. 1 showed activity against F. solani and 4 showed activity against
F. oxysporum and F. proliferatum after 48 hours exposure. Both lost activity after 72
hours. Captan and Amphotericin B showed activity against Fusarium spp. after 48 hours
but lost activity after 72 hours, while Azoxystrobin retained activity after 72 hours. All
compounds showed no activity after 72 hours, except for 8, which retained activity
against F. solani, and Azoxystrobin, which retained activity against Fusarium spp. At
the highest concentration (30 yuM), only compound 16 did not exhibit activity against
1 and all other analogues displaced activity after 48 and 72 hours of
These compounds showed greater activity that the standard Azoxystrobin.
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2.D.3. Fungistatic and Fungicidal Activity. The fungistatic (FS) and fungicidal (FC)
activity of 1 and its analogues was examined at 30 /iM against Fusarium spp. (Table 5).
Analysis was completed after 72 hours. The standards Amphotericin B, Captan, and
Azoxystrobin were tested and provided expected results. Amphotericin B is fungicidal
and Captan, and Azoxystrobin are fungistatic against Fusarium spp. 1 was fungicidal
against all three species of Fusarium tested. The analogues were consistently fungicidal
against Fusarium solani but varied in effect against Fusarium oxysporum and Fusarium
proliferatum. 16, prepared through amidation of KF with coumarin, showed no activity
against Fusarium spp. Results of this evaluation revealed that semisynthetic modification
of KF alters the activity against Fusarium spp. In particular, amidation with
results in elimination of activity.
coumarm
Table 5. Fungistatic (FS) and Fungicidal (FC) Activity of 1 and Its Analogues at 30 jM
against Fusarium spp.
Antifungal activity at 30 pM

















2.E. Cytotoxicity. Analogues 5, 7, 8, and 16 were evaluated for in vitro anticancer drug
screening in 60 human cancer cell lines. The cell lines tested included lung, leukemia,
colon, central ner\^ous system (CNS), melanoma, ovarian, renal, prostate, and breast. The
concentration needed to reduce the growth of treated cells to half that of untreated cells
(GIso - 50% inhibition of cell growth) and the concentration required to completely halt
the growth of treated cells (TGI - total growth inhibition) was determined using each
analogue with each cell line. These values were compared with the values of the current
chemotherapy drug, Paclitaxel. The TGI of the analogues exhibited higher cytotoxic
potency than Paclitaxel against most of the cell lines. The analogues exhibited significant
activity against non-small-cell lung (NSCL), colon, ovarian, breast, and prostate cancer
(Table 6). 5 showed better activity than 1 against the cell lines RPMI-8226 (leukemia),
HCC-2998 (colon), HT29 (colon), SK-OV-3 (ovarian), ACHN (renal), and PC-3
(prostate). 7, 8, and 16 showed better activity that 1 against NCI-H322M (NSCL). 7
and 8 showed better activity than 1 against HCC-2998 (colon). 5 showed increased
activity against most of the tested cell lines, while 16 showed loss of activity in most
Results of this evaluation revealed that improvements against selected cancer cellcases.
lines are possible from semisynthetic modification of 1.
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IV. CONCLUSION
It is quite evident that the diverse array of life housed within our world’s
ecosystems has pro\'ed itself in providing key elements in the treatment of various forms
of cancer and other diseases. And yet, after years of study, the NCI feels that we have
only scratched the surface on what is really out there. However, in an ever changing
world, research in the area of natural products for drug development “becomes a race
against time”. As species housed within our ecosystems continue to disappear and as
pathogens evolve and become resistant to current drug therapies, drug discovery is
For these reasons, continued research with the kahalalide family of compounds
As previously stated, evaluations of KF have shown significant activity
against various forms of cancer, including colon, breast, non-small-cell lung, and
prostate. KF has been investigated in phase I and phase II clinical trials for androgen-
refractory prostate cancer*^ and for liver cancer, NSCLC, and melanoma, respectively.^*
Patients with advanced NSCLC, HC, and AMM have also responded positively to
This study has confirmed that semisynthetic modifications of KF
positively affect antifungal activity, as well as the activity against a slate of human
cancer cell lines.
As previously discussed, the significant activity of KF against serious forms of
cancer, as well as fungi, has prompted research to investigate the mechanism of action of
the compound. It is thought that human ribosomal protein S25 (RPS25) is a binding
partner for KF. Research shows that this may only be one step in a series of events
leading to disruption of lysosomes and eventual cell death by oncosis. Further








understanding of the signaling pathway and mechanism of action of the parent
Research has also shown that inhibition of the receptor tyrosine kinase
ErbB3 (HER3) has an affect on the mechanism of action. Because there are currently no
ErbB3 (HER3) inhibiting drugs, KJF would serve as an excellent candidate for mhibition
Further semisynthetic modifications and lead-
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